'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
https://www.bloomberg.com/news/articles/2026-09-16/novartis-experimental-drug-for-als-fails-in-another-pipeline-hit
Stocks · News reference
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
- Reuters
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is Invesco S&P International Developed Quality ETF (IDHQ) a Strong ETF Right Now?
IDHQ is a smart beta ETF with $1.05 billion in assets that tracks high-quality international developed market stocks. It offers low expenses at 0.29%, strong year-to-date performance of 25.91%, and a low-risk profile with a beta of 0.92. The fund holds 213 stocks with top holdings including Roche, ASML, and Novartis.
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access
The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.